About: Development of a Laboratory-safe and Low-cost Detection Protocol for SARS-CoV-2 of the Coronavirus Disease 2019 (COVID-19)

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Development of a Laboratory-safe and Low-cost Detection Protocol for SARS-CoV-2 of the Coronavirus Disease 2019 (COVID-19) Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Development of a Laboratory-safe and Low-cost Detection Protocol for SARS-CoV-2 of the Coronavirus Disease 2019 (COVID-19)
Source	Medline; PMC
abstract	The severe acute respiratory coronavirus 2 (SARS-CoV-2), which emerged in December 2019 in Wuhan, China, has spread rapidly to over a dozen countries. Especially, the spike of case numbers in South Korea sparks pandemic worries. This virus is reported to spread mainly through person-to-person contact via respiratory droplets generated by coughing and sneezing, or possibly through surface contaminated by people coughing or sneezing on them. More critically, there have been reports about the possibility of this virus to transmit even before a virus-carrying person to show symptoms. Therefore, a low-cost, easy-access protocol for early detection of this virus is desperately needed. Here, we have established a real-time reverse-transcription PCR (rtPCR)-based assay protocol composed of easy specimen self-collection from a subject via pharyngeal swab, Trizol-based RNA purification, and SYBR Green-based rtPCR. This protocol shows an accuracy and sensitivity limit of 1-10 virus particles as we tested with a known lentivirus. The cost for each sample is estimated to be less than 15 US dollars. Overall time it takes for an entire protocol is estimated to be less than 4 hours. We propose a cost-effective, quick-and-easy method for early detection of SARS-CoV-2 at any conventional Biosafety Level II laboratories that are equipped with a rtPCR machine. Our newly developed protocol should be helpful for a first-hand screening of the asymptomatic virus-carriers for further prevention of transmission and early intervention and treatment for the rapidly propagating virus.
has issue date	2020-04-30(xsd:dateTime)
bibo:doi	10.5607/en20009
bibo:pmid	32156101
has license	cc-by-nc
sha1sum (hex)	4b8bf70628e4839431a958c230911f5d3d921fc3
schema:url	https://doi.org/10.5607/en20009
resource representing a document's title	Development of a Laboratory-safe and Low-cost Detection Protocol for SARS-CoV-2 of the Coronavirus Disease 2019 (COVID-19)
has PubMed Central identifier	PMC7237269
has PubMed identifier	32156101
schema:publication	Exp Neurobiol
resource representing a document's body	covid:4b8bf70628e4839431a958c230911f5d3d921fc3#body_text
is schema:about of	named entity 'SARS-CoV2' named entity 'RNA extraction' named entity 'viral RNA' named entity 'clinical diagnosis' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'diagnostic test' named entity 'Group A Streptococcus' named entity 'standard curve' named entity 'throat swab' named entity 'SARS-CoV-2' named entity 'RNA' named entity 'SARS-CoV-2' named entity 'tissue sample' named entity 'cDNA' named entity 'SARS-CoV-2' named entity 'gene' named entity 'rtPCR' named entity 'rt-PCR' named entity 'centrifuged' named entity 'RNA-dependent RNA polymerase' named entity 'rtPCR' named entity 'Taqman' named entity 'bacteria' named entity 'HEK293 cells' named entity 'DMEM' named entity 'rtPCR' named entity 'rtPCR' named entity 'tissue sample' named entity 'titer' named entity 'viral RNAs' named entity 'RNAse' named entity 'PCR' named entity 'CDC' named entity 'Lentivirus' named entity 'RNA' named entity 'Qiagen' named entity 'Trizol' named entity 'RNA' named entity 'Invitrogen' named entity 'cDNA' named entity 'viruses' named entity 'Trizol' named entity 'RNA' named entity 'SARS' named entity 'informed consent' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'schematic diagram' named entity 'SARS-CoV-2' named entity 'RNA' named entity 'SARS-CoV-2' named entity 'infection' named entity 'rt-PCR' named entity 'Dulbecco' named entity 'Trizol' named entity 'RNA extraction' named entity 'Asymptomatic' named entity 'Taqman' named entity 'DMEM' named entity 'primers' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'internal control' named entity 'fever' named entity 'SYBR Green' named entity 'SARS-CoV-2' named entity 'negative control' named entity 'non-infectious' named entity 'DMEM' named entity 'PCR' named entity 'RNA' named entity 'SARS-CoV-2' named entity 'Trizol' named entity 'RNA extraction' named entity 'health care worker' named entity 'asymptomatic people' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'internal control' named entity 'tissue sample'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software